BEAM - Beam Therapeutics Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

683.9M

Cash

1.19B

Avg Qtr Burn

-37.3M

Short % of Float

17.95%

Insider Ownership

1.83%

Institutional Own.

87.46%

Qtr Updated

12/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BEAM-201 Details Blood cancer, T-cell lymphoma, Cancer, Acute lymphoblastic leukemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BEAM-101 Details Beta thalessemia, Sickle cell disease	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BEAM-302 Details Alpha-1 Antitrypsin Deficiency	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.